THE Therapeutic Goods Administration is seeking comments from interested parties on a paper canvassing "Options for the Regulation of Faecal Microbiota Transplantation materials".
The therapy is increasing in prevalence in Australia, with the Gastroenterological Society of Australia recommending that Faecal Microbiota Transplantation (FMT) be made available as a treatment option for all patients with recurrent or refractory Clostridium difficile infection.
Feedback is sought by 15 Mar - for details see tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jan 19
